With this in mind, we used the same network pharmacological approach to validate two common SGLT2 inhibitors, namely, empagliflozin and canagliflozin, to determine whether their benefit in T2DM complicated with CVD is also related to the MAPK signalling pathway. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.